KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Finished Goods for 11 consecutive years, with $4.5 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Finished Goods rose 42.36% year-over-year to $4.5 million, compared with a TTM value of $4.5 million through Sep 2022, up 42.36%, and an annual FY2021 reading of $2.9 million, down 12.3% over the prior year.
  • Finished Goods was $4.5 million for Q3 2022 at TherapeuticsMD, up from $4.0 million in the prior quarter.
  • Across five years, Finished Goods topped out at $5.0 million in Q3 2019 and bottomed at $1.6 million in Q1 2018.
  • Average Finished Goods over 5 years is $3.4 million, with a median of $3.3 million recorded in 2019.
  • The sharpest move saw Finished Goods surged 122.24% in 2019, then tumbled 41.45% in 2021.
  • Year by year, Finished Goods stood at $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then plummeted by 32.69% to $3.4 million in 2020, then decreased by 12.3% to $2.9 million in 2021, then skyrocketed by 54.42% to $4.5 million in 2022.
  • Business Quant data shows Finished Goods for TXMD at $4.5 million in Q3 2022, $4.0 million in Q2 2022, and $3.3 million in Q1 2022.